Loading...

Zealand Pharma

CPSE:ZEAL
Snowflake Description

Proven track record with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ZEAL
CPSE
DKK5B
Market Cap
  1. Home
  2. DK
  3. Pharmaceuticals & Biotech
Company description

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. The last earnings update was 6 days ago. More info.


Add to Portfolio Compare Print
  • Zealand Pharma has significant price volatility in the past 3 months.
ZEAL Share Price and Events
7 Day Returns
8.4%
CPSE:ZEAL
6.8%
DK Biotechs
1.2%
DK Market
1 Year Returns
46.9%
CPSE:ZEAL
-3.5%
DK Biotechs
-0.6%
DK Market
ZEAL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Zealand Pharma (ZEAL) 8.4% 22.1% 55.6% 46.9% 13% 132.3%
DK Biotechs 6.8% 6.8% 17.7% -3.5% -5.6% 318.5%
DK Market 1.2% -0.7% 1.6% -0.6% 3.1% 35.7%
1 Year Return vs Industry and Market
  • ZEAL outperformed the Biotechs industry which returned -3.5% over the past year.
  • ZEAL outperformed the Market in Denmark which returned -0.6% over the past year.
Price Volatility
ZEAL
Industry
5yr Volatility vs Market

ZEAL Value

 Is Zealand Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Zealand Pharma. This is due to cash flow or dividend data being unavailable. The share price is DKK147.5.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Zealand Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Zealand Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CPSE:ZEAL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in DKK DKK17.93
CPSE:ZEAL Share Price ** CPSE (2019-05-22) in DKK DKK147.5
Europe Biotechs Industry PE Ratio Median Figure of 29 Publicly-Listed Biotechs Companies 20.63x
Denmark Market PE Ratio Median Figure of 103 Publicly-Listed Companies 16.22x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Zealand Pharma.

CPSE:ZEAL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CPSE:ZEAL Share Price ÷ EPS (both in DKK)

= 147.5 ÷ 17.93

8.22x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Zealand Pharma is good value based on earnings compared to the Europe Biotechs industry average.
  • Zealand Pharma is good value based on earnings compared to the Denmark market.
Price based on expected Growth
Does Zealand Pharma's expected growth come at a high price?
Raw Data
CPSE:ZEAL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 8.22x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
6.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 23 Publicly-Listed Biotechs Companies 1.25x
Denmark Market PEG Ratio Median Figure of 44 Publicly-Listed Companies 2.14x

*Line of best fit is calculated by linear regression .

CPSE:ZEAL PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 8.22x ÷ 6.2%

1.33x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Zealand Pharma is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Zealand Pharma's assets?
Raw Data
CPSE:ZEAL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in DKK DKK35.12
CPSE:ZEAL Share Price * CPSE (2019-05-22) in DKK DKK147.5
Denmark Biotechs Industry PB Ratio Median Figure of 6 Publicly-Listed Biotechs Companies 3.37x
Denmark Market PB Ratio Median Figure of 135 Publicly-Listed Companies 1.64x
CPSE:ZEAL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CPSE:ZEAL Share Price ÷ Book Value per Share (both in DKK)

= 147.5 ÷ 35.12

4.2x

* Primary Listing of Zealand Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Zealand Pharma is overvalued based on assets compared to the DK Biotechs industry average.
X
Value checks
We assess Zealand Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Zealand Pharma has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ZEAL Future Performance

 How is Zealand Pharma expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
6.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Zealand Pharma expected to grow at an attractive rate?
  • Zealand Pharma's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Zealand Pharma's earnings growth is positive but not above the Denmark market average.
  • Zealand Pharma's revenue growth is expected to exceed the Denmark market average.
Annual Growth Rates Comparison
Raw Data
CPSE:ZEAL Future Growth Rates Data Sources
Data Point Source Value (per year)
CPSE:ZEAL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 6.2%
CPSE:ZEAL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 22.9%
Denmark Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 23.5%
Europe Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 14.3%
Denmark Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Denmark Market Revenue Growth Rate Market Cap Weighted Average 6.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CPSE:ZEAL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in DKK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CPSE:ZEAL Future Estimates Data
Date (Data in DKK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 381 -348 7 3
2022-12-31 200 -442 -344 3
2021-12-31 173 -301 -300 5
2020-12-31 183 -361 -363 6
2019-12-31 167 -295 -353 6
CPSE:ZEAL Past Financials Data
Date (Data in DKK Millions) Revenue Cash Flow Net Income *
2019-03-31 28 -319 551
2018-12-31 38 -460 581
2018-09-30 39 -417 597
2018-06-30 78 -310 -370
2018-03-31 72 -320 -338
2017-12-31 136 -279 -275
2017-09-30 306 -64 -112
2017-06-30 307 -113 -100
2017-03-31 306 -52 -102
2016-12-31 231 41 -157
2016-09-30 221 -114 -138
2016-06-30 189 -128 -158

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Zealand Pharma's earnings are expected to grow by 6.2% yearly, however this is not considered high growth (20% yearly).
  • Zealand Pharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CPSE:ZEAL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Zealand Pharma Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CPSE:ZEAL Future Estimates Data
Date (Data in DKK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -11.80 -11.80 -11.80 1.00
2022-12-31 -14.80 -14.80 -14.80 1.00
2021-12-31 -10.36 -8.20 -12.72 3.00
2020-12-31 -10.51 -8.20 -13.30 5.00
2019-12-31 -10.35 -8.60 -11.20 4.00
CPSE:ZEAL Past Financials Data
Date (Data in DKK Millions) EPS *
2019-03-31 17.93
2018-12-31 18.94
2018-09-30 19.23
2018-06-30 -12.18
2018-03-31 -11.61
2017-12-31 -9.88
2017-09-30 -4.26
2017-06-30 -3.96
2017-03-31 -4.14
2016-12-31 -6.47
2016-09-30 -5.78
2016-06-30 -6.69

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Zealand Pharma will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Zealand Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Denmark market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Zealand Pharma has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ZEAL Past Performance

  How has Zealand Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Zealand Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Zealand Pharma has delivered over 20% year on year earnings growth in the past 5 years.
  • Zealand Pharma has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Zealand Pharma has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Earnings and Revenue History
Zealand Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Zealand Pharma Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CPSE:ZEAL Past Revenue, Cash Flow and Net Income Data
Date (Data in DKK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 28.26 551.13 56.69 464.09
2018-12-31 37.98 581.28 50.24 431.52
2018-09-30 38.83 596.59 52.73 397.83
2018-06-30 77.92 -370.32 51.50 382.59
2018-03-31 71.88 -338.31 49.92 343.57
2017-12-31 136.32 -275.26 53.57 318.57
2017-09-30 306.31 -111.86 57.86 292.88
2017-06-30 306.80 -99.64 55.13 274.25
2017-03-31 305.66 -102.43 60.97 259.10
2016-12-31 230.86 -157.30 58.60 262.06
2016-09-30 221.38 -137.86 51.26 243.16
2016-06-30 189.02 -157.94 55.03 237.42
2016-03-31 188.38 -138.53 47.86 223.60
2015-12-31 187.68 -113.96 47.82 211.74
2015-09-30 26.87 -245.71 47.55 217.05
2015-06-30 77.82 -177.87 44.32 212.27
2015-03-31 74.82 -147.07 39.33 194.90
2014-12-31 153.77 -64.99 39.83 180.04
2014-09-30 150.65 -46.80 31.24 160.24
2014-06-30 94.79 -98.25 32.97 150.74
2014-03-31 91.57 -97.50 35.09 147.14
2013-12-31 6.57 -183.68 34.16 164.47
2013-09-30 3.40 -191.37 33.93 177.37
2013-06-30 38.45 -157.36 32.91 186.25
2013-03-31 103.28 -86.64 28.61 194.83
2012-12-31 223.57 36.37 27.61 182.76
2012-09-30 245.88 69.67 26.76 169.47
2012-06-30 209.18 55.94 28.14 148.43

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Zealand Pharma made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).
  • Zealand Pharma used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Zealand Pharma has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Zealand Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Zealand Pharma has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ZEAL Health

 How is Zealand Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Zealand Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Zealand Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Zealand Pharma has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Zealand Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 217.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Zealand Pharma Company Filings, last reported 1 month ago.

CPSE:ZEAL Past Debt and Equity Data
Date (Data in DKK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 1,084.29 5.95 1,263.31
2018-12-31 1,116.28 0.00 1,159.25
2018-09-30 1,240.77 0.00 1,478.61
2018-06-30 316.24 143.44 461.34
2018-03-31 437.06 134.15 561.10
2017-12-31 514.67 135.73 663.83
2017-09-30 638.98 141.90 774.65
2017-06-30 181.53 146.05 302.11
2017-03-31 252.69 161.49 410.27
2016-12-31 278.19 332.24 323.33
2016-09-30 217.63 312.15 224.64
2016-06-30 107.52 311.22 289.36
2016-03-31 178.64 301.93 358.76
2015-12-31 252.23 312.95 418.80
2015-09-30 159.43 333.23 453.89
2015-06-30 163.04 301.12 468.61
2015-03-31 209.18 308.69 523.98
2014-12-31 252.83 272.17 516.85
2014-09-30 316.22 0.00 303.81
2014-06-30 299.36 0.00 297.62
2014-03-31 344.99 0.00 349.65
2013-12-31 316.14 0.00 310.56
2013-09-30 361.90 0.00 357.83
2013-06-30 396.03 0.00 403.58
2013-03-31 442.55 0.00 441.30
2012-12-31 491.02 0.00 485.79
2012-09-30 536.66 0.00 498.33
2012-06-30 536.79 0.00 524.96
  • Zealand Pharma's level of debt (0.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 0.5% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Interest payments on debt are well covered by earnings (EBIT is 36.5x coverage).
X
Financial health checks
We assess Zealand Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Zealand Pharma has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ZEAL Dividends

 What is Zealand Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Zealand Pharma dividends. Estimated to be 0% next year.
If you bought DKK2,000 of Zealand Pharma shares you are expected to receive DKK0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Zealand Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Zealand Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CPSE:ZEAL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
Denmark Market Average Dividend Yield Market Cap Weighted Average of 78 Stocks 2.5%
Denmark Minimum Threshold Dividend Yield 10th Percentile 1%
Denmark Bottom 25% Dividend Yield 25th Percentile 1.6%
Denmark Top 25% Dividend Yield 75th Percentile 4.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CPSE:ZEAL Future Dividends Estimate Data
Date (Data in DKK) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Zealand Pharma has not reported any payouts.
  • Unable to verify if Zealand Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Zealand Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Zealand Pharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Zealand Pharma's dividends in 3 years as they are not expected to pay a notable one for Denmark.
X
Income/ dividend checks
We assess Zealand Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Zealand Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Zealand Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ZEAL Management

 What is the CEO of Zealand Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Emmanuel Dulac
AGE 48
TENURE AS CEO 0.1 years
CEO Bio

Dr. Emmanuel Dulac, PharmD, PhD, MBA, has been Chief Executive Officer at Zealand Pharma A/S since April 22, 2019 and its President since 2019. He had been Chief Commercial Officer and Senior Vice President of Alnylam Pharmaceuticals, Inc. from September 19, 2016 to June 2018 and its Chief International Strategy since August 2016. Dr. Dulac has more than 20 years of international experience in the biotech and pharmaceutical industry. He joined Alnylam Pharmaceuticals, from Shire, where he was Senior Vice President, Global Head of the Rare Disease Business Unit and General Manager of United States Operations from June 2014 to August 2016. Dr. Dulac held several leadership roles of increasing responsibility at Novartis (NYSE:NVS) from February 2006 to May 2014, including Vice President, Global Head Lung/Cystic Fibrosis. From August 2003 to February 2006, he was Business Unit Lead for Cardiovascular Medicine at Abbott (NYSE:ABT). Dr. Dulac held several roles of increasing responsibility at Sanofi (NASDAQ:SNY) from October 1994 to August 2003, including Associate Director. During his career, he successfully launched six brands, led two blockbuster drugs globally and built large sales organizations, innovative patient services and strong marketing and market access teams. He has been a Director of Proteostasis Therapeutics, Inc. since February 5, 2019. He graduated from the University of Paris XI with a Doctorate in Pharmacology (PharmD, Ph.D.) and completed an MBA from the ESSEC School in Paris.

CEO Compensation
  • Insufficient data for Emmanuel to compare compensation growth.
  • Insufficient data for Emmanuel to establish whether their remuneration is reasonable compared to companies of similar size in Denmark.
Management Team Tenure

Average tenure and age of the Zealand Pharma management team in years:

1.7
Average Tenure
50
Average Age
  • The average tenure for the Zealand Pharma management team is less than 2 years, this suggests a new team.
Management Team

Hanne Bak

TITLE
Senior Project Director
COMPENSATION
DKK300K
AGE
65
TENURE
5.1 yrs

Emmanuel Dulac

TITLE
CEO & President
AGE
48
TENURE
0.1 yrs

Ivan Møller

TITLE
Interim CFO and Senior VP of Technical Development & Operations
AGE
46

Andy Parker

TITLE
Executive VP & Chief Science Officer
AGE
53
TENURE
2.8 yrs

Lani Morvan

TITLE
Investor Relations & Communications Officer

Søren Keller

TITLE
Head of Legal Affairs
TENURE
5.1 yrs

Marino Garcia

TITLE
Senior Vice President of Corporate & Business Development
AGE
52
TENURE
0.6 yrs

Niels Mørk

TITLE
Head of Bioanalysis

Jens Mikkelsen

TITLE
Head of Molecular Pharmacology

Adam Steensberg

TITLE
Executive VP and Chief Medical & Development Officer
AGE
44
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Zealand Pharma board of directors in years:

7.5
Average Tenure
64
Average Age
  • The tenure for the Zealand Pharma board of directors is about average.
Board of Directors

Martin Nicklasson

TITLE
Chairman of the Board
COMPENSATION
DKK750K
AGE
63
TENURE
4.1 yrs

Kirsten Drejer

TITLE
Vice Chairman
COMPENSATION
DKK200K
AGE
62
TENURE
0.1 yrs

Hanne Bak

TITLE
Senior Project Director
COMPENSATION
DKK300K
AGE
65
TENURE
3.1 yrs

Alain Munoz

TITLE
Co-Chair of the Clinical & Scientific Advisory Board & Director
COMPENSATION
DKK350K
AGE
69
TENURE
7.5 yrs

Leon Kruimer

TITLE
Director
AGE
60
TENURE
0.1 yrs

Tyge Korsgaard

TITLE
Board Observer

Bernard Charbonnel

TITLE
Member of Advisory Board
TENURE
7.5 yrs

Richard Pratley

TITLE
Member of Advisory Board
TENURE
7.5 yrs

Paul Dorian

TITLE
Member of Advisory Board
TENURE
7.5 yrs

Ake Lernmark

TITLE
Member of Advisory Board
AGE
73
TENURE
7.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (DKK) Value (DKK)
X
Management checks
We assess Zealand Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Zealand Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ZEAL News

Simply Wall St News

Is Zealand Pharma A/S's (CPH:ZEAL) 48% Better Than Average?

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … Our data shows Zealand Pharma has a return on equity of 48% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Should You Be Concerned About Zealand Pharma A/S's (CPH:ZEAL) Investors?

In this article, I'm going to take a look at Zealand Pharma A/S’s (CPH:ZEAL) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … The impact of a company's ownership structure affects both its short- and long-term performance. … See our latest analysis for Zealand Pharma

Simply Wall St -

Zealand Pharma A/S's (CPH:ZEAL) Path To Profitability

Zealand Pharma A/S's (CPH:ZEAL):. … Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. … The ø2.90b market-cap posted a loss in its most recent financial year of -ø272.27m and a latest trailing-twelve-month loss of -ø337.35m leading to an even wider gap between loss and breakeven?

Simply Wall St -

What Are Analysts Saying About The Future Of Zealand Pharma A/S's (CPH:ZEAL)?

Zealand Pharma A/S's (CPSE:ZEAL) released its most recent earnings update in December 2017, which confirmed company earnings became less negative compared to the previous year's level - great news for investors Below, I've laid out key numbers on how market analysts predict Zealand Pharma's earnings growth outlook over the next couple of years and whether the future looks brighter. … See our latest analysis for Zealand Pharma Analysts' outlook for this coming year seems pessimistic, with earnings becoming even more negative, arriving at -Ø389.33M in 2019. … Future Earnings: How does ZEAL's growth rate compare to its peers and the wider market?

Simply Wall St -

Zealand Pharma A/S (CPH:ZEAL): When Will It Breakeven?

Many investors are wondering the rate at which ZEAL will turn a profit, with the big question being “when will the company breakeven?” I’ve put together a brief outline of industry analyst expectations for ZEAL, its year of breakeven and its implied growth rate. … See our latest analysis for Zealand Pharma Expectation from analysts is ZEAL is on the verge of breakeven. … How fast will ZEAL have to grow each year in order to reach the breakeven point by 2022?

Simply Wall St -

Analysts Bearish On Zealand Pharma A/S (CPH:ZEAL)

Given its debt level is relatively minimal (-205.36% of equity), the fact that ZEAL's cash only covers a mere -205.36% of debt makes me uneasy. … There's room for improvement on the cash management side of things, but its overall debt level and interest coverage somewhat increases my conviction of the sustainability of the business going forward. … One reason I do like ZEAL as a business is its low level of fixed assets on its balance sheet (2.19% of total assets).

Simply Wall St -

Should You Be Concerned With Zealand Pharma A/S's (CPH:ZEAL) -76.90% Earnings Drop?

Measuring Zealand Pharma A/S's (CPSE:ZEAL) track record of past performance is a useful exercise for investors. … See our latest analysis for Zealand Pharma How Did ZEAL's Recent Performance Stack Up Against Its Past? … For Zealand Pharma, its latest earnings (trailing twelve month) is -Ø272.27M, which, against the prior year's figure, has become more negative.

Simply Wall St -

ZEAL Company Info

Description

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company’s product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH; and Alexion Pharmaceuticals, Inc. for the discovery and development of peptide therapies for complement-mediated diseases. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

Details
Name: Zealand Pharma A/S
ZEAL
Exchange: CPSE
Founded: 1997
DKK4,663,317,667
31,615,713
Website: http://www.zealandpharma.com
Address: Zealand Pharma A/S
Smedeland 36,
Glostrup,
Copenhagen,
Capital Region of Denmark, 2600,
Denmark
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CPSE ZEAL Ordinary Shares OMX Nordic Exchange Copenhagen DK DKK 23. Nov 2010
OTCPK ZLDP.F Ordinary Shares Pink Sheets LLC US USD 23. Nov 2010
DB 22Z Ordinary Shares Deutsche Boerse AG DE EUR 23. Nov 2010
LSE 0NZU Ordinary Shares London Stock Exchange GB DKK 23. Nov 2010
BATS-CHIXE ZEALC Ordinary Shares BATS 'Chi-X Europe' GB DKK 23. Nov 2010
NasdaqGS ZEAL SPONSORED ADR Nasdaq Global Select US USD 09. Aug 2017
DB 22ZA SPONSORED ADR Deutsche Boerse AG DE EUR 09. Aug 2017
Number of employees
Current staff
Staff numbers
149
Zealand Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/22 21:26
End of day share price update: 2019/05/22 00:00
Last estimates confirmation: 2019/05/21
Last earnings filing: 2019/05/16
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.